B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
0
Authors
Adam Cohen•Alfred Garfall•Michael Milone
Published
March 21, 2019
Abstract
BACKGROUND. CAR T cells are a promising therapy for hematologic malignancies. B cell maturation antigen (BCMA) is a rational target in multiple myeloma (MM).
